Lupus Trial, Recruiting NCT07515638 Sponsor: University Hospital, Montpellier Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT07515638
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 – Rheumatoid Arthritis (RA):

  • Adults aged 18 or older
  • People currently being treated and monitored at a participating department at University Hospital of Montpellier (UHM) for an autoimmune condition
  • People with a confirmed diagnosis of rheumatoid arthritis based on internationally recognised diagnostic standards (ACR/EULAR 2010 criteria)

Group 2 – Lupus (SLE):

  • Adults aged 18 or older
  • People currently being treated and monitored at a participating department at UHM for an autoimmune condition
  • People with a confirmed diagnosis of lupus based on internationally recognised diagnostic standards (ACR/EULAR 2019 criteria)

Group 3 – Systemic Sclerosis (SSc):

  • Adults aged 18 or older
  • People currently being treated and monitored at a participating department at UHM for an autoimmune condition
  • People with a confirmed diagnosis of systemic sclerosis based on internationally recognised diagnostic standards (ACR/EULAR 2013 criteria)

Group 4 – Healthy Volunteers:

  • Adults aged 18 or older
  • People with no symptoms of any autoimmune disease
  • People with no parent, sibling, or child who has been diagnosed with an autoimmune disease

Who may not be able to join:

  • People who have declined to give informed consent, or who are not able to give it
  • People who would not be able to be followed up for the full duration of the study
  • People currently participating in another clinical trial that has an ongoing exclusion period
  • People who are pregnant
  • People who are not enrolled in a French social security (health insurance) scheme
  • People who do not have a French national insurance number
  • People who are under legal protection orders, guardianship, or trusteeship
  • People who are currently deprived of their liberty

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yves-Marie PERS, Pr, Montpellier University Hospital

Phone: +334 67 33 48 53

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
23 June 2026
Est. completion
23 June 2031

Where this trial is recruiting

🇫🇷 France

Primary endpoints

AUC-ROC discriminant performance of multi-omic biomarkers

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov